Halozyme Therapeutics Inc (HALO)
46.93
-0.39
(-0.82%)
USD |
NASDAQ |
Dec 20, 16:00
46.95
+0.02
(+0.04%)
After-Hours: 20:00
Halozyme Therapeutics PS Ratio: 6.432 for Dec. 20, 2024
PS Ratio Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
Price to Sales Ratio Definition
The Price to Sales Ratio (PS Ratio) is calculated by taking the stock price / revenue per share (ttm). This metric is considered a valuation metric that confirms whether the sales of a company justifies the stock price. There isn't necesarily an optimum PS ratio, since different industries will have different ranges of PS Ratios. Because of this, PS Ratio is great to evaluate from a relative standpoint with other similar companies. PS Ratio might also be a handy metric for companies that are not profitable yet, since they might be valued moreso by their overall sales and potential of becoming profitable in the future.
PS Ratio Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
PS Ratio Benchmarks
| Lexicon Pharmaceuticals Inc | 39.74 |
| Novavax Inc | 1.517 |
| Kura Oncology Inc | -- |
| TransMedics Group Inc | 5.322 |
| Pulmonx Corp | 3.015 |
PS Ratio Related Metrics
| PE Ratio | 15.54 |
| PEG Ratio | 0.2563 |
| Price to Book Value | 13.19 |
| Price to Free Cash Flow | 15.52 |
| Price | 46.93 |
| Earnings Yield | 6.44% |
| Market Cap | 5.971B |
| PEGY Ratio | 0.2563 |
| Operating PE Ratio | 12.77 |
| Normalized PE Ratio | 16.28 |